Viking Therapeutics Inc (NASDAQ: VKTX) on Friday, soared 3.32% from the previous trading day, before settling in for the closing price of $29.50. Within the past 52 weeks, VKTX’s price has moved between $28.64 and $99.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -57.98%. With a float of $107.93 million, this company’s outstanding shares have now reached $111.57 million.
In an organization with 27 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 28.9%, operating margin of -30726.61%, and the pretax margin is -22741.06%.
Viking Therapeutics Inc (VKTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viking Therapeutics Inc is 3.14%, while institutional ownership is 74.48%. The most recent insider transaction that took place on Jan 06 ’25, was worth 8,313,601. In this transaction President & CEO of this company sold 194,490 shares at a rate of $42.75, taking the stock ownership to the 2,366,570 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Operating Officer sold 54,215 for $42.75, making the entire transaction worth $2,317,599. This insider now owns 374,134 shares in total.
Viking Therapeutics Inc (VKTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -57.98% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Viking Therapeutics Inc (VKTX) is currently performing well based on its current performance indicators. A quick ratio of 36.47 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -2.16 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.95 million. That was inferior than the volume of 4.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.97%. Additionally, its Average True Range was 2.08.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 3.47%, which indicates a significant decrease from 29.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.94% in the past 14 days, which was lower than the 74.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.90, while its 200-day Moving Average is $55.41. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $31.07. Second resistance stands at $31.67. The third major resistance level sits at $32.45. If the price goes on to break the first support level at $29.69, it is likely to go to the next support level at $28.91. Assuming the price breaks the second support level, the third support level stands at $28.31.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
Market capitalization of the company is 3.40 billion based on 111,436K outstanding shares. Right now, sales total 0 K and income totals -109,960 K. The company made 0 K in profit during its latest quarter, and -35,420 K in sales during its previous quarter.
